SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): KNP-301

            Therapeutic Area: Ophthalmology Product Name: KNP-301

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kanaph Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership September 24, 2020

            Details:

            Samsung Biologics will provide a full scope of its CDO services from cell line development, process development, non-clinical and clinical material manufacturing to IND submission for KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.